UK markets close in 6 hours 47 minutes

Neurocrine Biosciences, Inc. (0K6R.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
98.91+0.81 (+0.83%)
As of 05:32PM BST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.70
52-week change 3N/A
S&P500 52-week change 3-13.03%
52-week high 398.91
52-week low 397.30
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 590.68M
Implied shares outstanding 6N/A
Float 894.3M
% held by insiders 11.34%
% held by institutions 199.03%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)31 Mar 2022

Profitability

Profit margin 5.91%
Operating margin (ttm)14.86%

Management effectiveness

Return on assets (ttm)5.62%
Return on equity (ttm)5.50%

Income statement

Revenue (ttm)1.21B
Revenue per share (ttm)12.73
Quarterly revenue growth (yoy)31.30%
Gross profit (ttm)791.1M
EBITDA 191.1M
Net income avi to common (ttm)71.4M
Diluted EPS (ttm)0.73
Quarterly earnings growth (yoy)-56.70%

Balance sheet

Total cash (mrq)664.9M
Total cash per share (mrq)6.96
Total debt (mrq)497.1M
Total debt/equity (mrq)35.73
Current ratio (mrq)4.02
Book value per share (mrq)14.57

Cash flow statement

Operating cash flow (ttm)128.7M
Levered free cash flow (ttm)152.58M